Clinical trials: Thromboses, Venous
Macular Edema, Retinal Vein Occlusion
An Extension Study to Evaluate Safety and Tolerability of Ranibizumab in Macular Edema Secondary to Retinal Vein Occlusion (Cohort 2)
This is an open-label, multicenter, extension study of intravitreally administered ranibizumab in two cohorts. The first cohort (reported separately under FVF3426g, NCT00379795) enrolled subjects with primary or recurrent…
- Trial name
- NCT01442064
- Testing
- Ranibizumab 0.5 mg
- Volunteers
- 608 people
- Sponsor
- Genentech, Inc.
Macular Edema, Branch Retinal Vein Occlusion
A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Branch Retinal Vein Occlusion
This is a Phase III, multicenter, randomized, double-masked, active comparator-controlled, parallel-group study evaluating the efficacy, safety, and pharmacokinetics of faricimab administered by intravitreal (IVT) injection at…
- Trial name
- BALATON (NCT04740905)
- Testing
- Faricimab, Aflibercept
- Where
- 150 sites in United States, Argentina and 20 more
- Volunteers
- 553 people
- Sponsor
- Hoffmann-La Roche
Venous Thromboembolism
Efficacy of Sodium Heparin for Prophylaxis of Venous Thromboembolism in Surgical Patients
The aim of this study is to verify, through clinical examination and doppler, the non-inferiority of the drug test (heparin sodium 5.000UI/0.25 mL - HIPOLABOR) in relation to the drug compared (heparin sodium 5.000USP/mL - APP)…
- Trial name
- NCT00934167
- Testing
- heparin sodium - Hipolabor, Heparin sodium - APP
- Where
- Brazil
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- Azidus Brasil
Multiple Myeloma, Myelodysplastic Syndromes
A Study of Special Use Results Surveillance of Revlimid 5mg Capsules
To understand the safety and efficacy of Revlimid® 5 mg Capsules (hereinafter referred to as Revlimid) in all patients who are treated with it under the actual condition of use pursuant to the conditions of approval. 1.
- Trial name
- NCT02921802
- Where
- Japan
- Volunteers
- 4,626 people
- Sponsor
- Celgene
Thrombosis, Venous
A Study to Evaluate the Efficacy and Safety of Fondaparinux for the Prevention of Venous Blood Clots in Patients With a Plaster Cast or Other Type of Immobilization for a Below-knee Injury Not Needing Surgery
The purpose of this study is to evaluate the efficacy and safety of fondaparinux in comparison with a heparin (nadroparin) in preventing deep vein thrombosis (blood clots in the leg veins), whether symptomatic or detected by…
- Trial name
- FONDACAST (NCT00843492)
- Testing
- Fondaparinux sodium, Nadroparin
- Where
- 122 sites in France, Germany and 4 more
- Volunteers
- 1,351 people
- Sponsor
- GlaxoSmithKline
Macular Edema Secondary to Branch Retinal Vein Occlusion
Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Branch Retinal Vein Occlusion (BRVO)
Provided efficacy and safety data on intravitreal injections of ranibizumab 0.5 mg in patients with visual impairment due to macular edema secondary to BRVO
- Trial name
- Blossom (NCT01976338)
- Testing
- Ranibizumab 0.5 mg
- Where
- 33 sites in China, Hong Kong and 4 more
- Volunteers
- 283 people
- Sponsor
- Novartis Pharmaceuticals
Venous Thromboembolism (VTE)
Treatment and Secondary Prevention of Venous Thromboembolism (VTE) in Adult Participants With Solid and Hematologic Cancers
This study is researching an experimental drug called REGN7508 (called "study drug") and will consist of 2 parts: Part 1 and Part 2.
- Trial name
- ROXI-CAT-II (NCT07493304)
- Testing
- REGN7508, Apixaban
- Where
- 14 sites in United States, Bulgaria and 3 more
- Volunteers
- 1,600 people
- Sponsor
- Regeneron Pharmaceuticals
Acute Coronary Syndrome, Venous Thrombosis
Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Practice (Sweden)
This prospective cohort study will provide information about: Characteristics of Rivaroxaban use in patients who are prescribed Rivaroxaban for the first time compared to patients who are prescribed standard of care for the first…
- Conditions
- Acute Coronary Syndrome, Venous Thrombosis, Pulmonary Embolism, Atrial Fibrillation
- Trial name
- NCT02468102
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Standard of care drugs
- Where
- Sweden
- Volunteers
- 99,999 people
- Sponsor
- Bayer
Pulmonary Embolism and Thrombosis
An International Pulmonary Embolism Registry Using EKOS
This registry is designed to understand acoustic pulse thrombolysis (APT) treatment regimens used as standard of care globally for pulmonary embolism.
- Trial name
- KNOCOUT PE (NCT03426124)
- Testing
- EkoSonic Endovascular System with thrombolytic
- Where
- 80 sites in United States, Austria and 6 more
- Volunteers
- 1,480 people
- Sponsor
- Boston Scientific Corporation
Venous Thromboses
BRAVO - Betrixaban Registry Using Real Time Observations in Acute Medical Illness to Assess Venous Thrombosis and Bleeding Outcomes
Part 1 - Evaluate the real-world implementation of extended prophylaxis with betrixaban in the acutely ill hospitalized medical population Part 2 - Describe patterns of Venous thromboembolism (VTE) prophylaxis in acutely ill…
- Trial name
- NCT03613402
- Where
- United States
- Sponsor
- Portola Pharmaceuticals
Deep Vein Thrombosis, Venous Thromboembolism
Phase 1 Pediatric Pharmacokinetics/Pharmacodynamics (PK/PD) Study
This is the first evaluation of edoxaban in pediatric subjects. In this Phase 1 study, a single dose of edoxaban will be given to pediatric subjects who require anticoagulant therapy to see what the body does to the drug…
- Trial name
- NCT02303431
- Testing
- Edoxaban low dose, Edoxaban high dose
- Where
- 35 sites in United States, Canada and 7 more
- Volunteers
- 66 people
- Sponsor
- Daiichi Sankyo
Venous Thromboses, Ischemic Stroke
OsciPulse D-dimer Efficacy Trial
The purpose of this study is to assess the safety and efficacy of the OsciPulse System in reducing serum d-dimer levels in hospitalized ischemic stroke patients.
- Trial name
- NCT05389488
- Testing
- OsciPulse system, Flowtron ACS900
- Where
- United States
- Sponsor
- OsciFlex LLC
Retinal Vein Occlusion
Prospective, Non-interventional, Multi-center Post-authorization Safety Study of Eylea for Central Retinal Vein Occlusion (CRVO)
This is a prospective, non-interventional, multi center post-authorization safety study that includes patients with a diagnosis of CRVO.
- Trial name
- JPMS-CRVO (NCT02040220)
- Testing
- Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
- Where
- Japan
- Volunteers
- 385 people
- Sponsor
- Bayer
Macular Edema, Retinal Vein Occlusion
A Study of the Efficacy and Safety of Ranibizumab Injection in Patients With Macular Edema Secondary to Branch Retinal Vein Occlusion (BRAVO)
This was a Phase III, multicenter, randomized, double-masked, sham injection-controlled study of the efficacy and safety of intravitreal ranibizumab compared with sham injections in patients with macular edema secondary to branch…
- Trial name
- BRAVO (NCT00486018)
- Testing
- Ranibizumab injection 0.3 mg, Ranibizumab injection 0.5 mg
- Volunteers
- 397 people
- Sponsor
- Genentech, Inc.
Venous Thromboembolism
A Study in the United Sates That Looks at the Safety and Effectiveness of Pradaxa Pellets in Children Aged 3 Months to Less Than 12 Years Who Need Treatment of a Blood Clot or Who Have Had a Blood Clot and Are at Risk of Developing Another Blood Clot
The main research question of this study is to obtain further safety and effectiveness data on Pradaxa Pellets in children aged 3 months to less than 12 years in routine clinical practice setting.
- Trial name
- NCT05966740
- Where
- 10 sites in United States
- Volunteers
- 5 people
- Sponsor
- Boehringer Ingelheim
Intraocular Inflammation, Suspected Endophthalmitis
A Study of the Incidence of Intraocular Inflammation and Suspected Endophthalmitis Among Patients Treated With Aflibercept, Vial and Pre-filled Syringe, 2014-2022
Specific study objectives include: To describe patient and provider characteristics for aflibercept patients and aflibercept user injections by aflibercept dispensing device, overall, and stratified by time (quarterly, annually).
- Trial name
- NCT05791695
- Testing
- Non Applicable
- Where
- United States
- Volunteers
- 155,413 people
- Sponsor
- Regeneron Pharmaceuticals
Abdominal Neoplasms
Japanese Efficacy and Safety Study of Enoxaparin in Patients With Curative Abdominal Cancer Surgery
The primary objective of this study is to evaluate the effects of enoxaparin on venous thromboembolism incidence and bleeding rate (major and minor bleeding) in patients undergoing curative abdominal cancer surgery.
- Trial name
- NCT00723216
- Testing
- enoxaparin, Physical prophylaxis
- Where
- Japan
- Volunteers
- 151 people
- Sponsor
- Sanofi
Macular Edema, Retinal Vein Occlusion
Suprachoroidal Injection of Triamcinolone Acetonide With IVT Anti-VEGF in Subjects With Macular Edema Following RVO
This Phase 3, multicenter, randomized, masked, controlled, parallel group study is designed to demonstrate that suprachoroidal (SC) CLS-TA administered with intravitreal (IVT) anti-VEGF agent in subjects with treatment naive RVO…
- Trial name
- TOPAZ (NCT03203447)
- Testing
- suprachoroidal CLS-TA, Lucentis or Avastin
- Where
- 92 sites in United States, Australia and 3 more
- Volunteers
- 325 people
- Sponsor
- Clearside Biomedical, Inc.
Retinal Vein Occlusion, Macular Edema
A Retrospective Study of Anti-Vascular Endothelial Growth Factor (VEGF) Injections for Retinal Vein Occlusion or Diabetic Macular Edema
This retrospective data review study will evaluate anti-VEGF injections for retinal vein occlusion (RVO) or diabetic macular edema (DME).
- Trial name
- NCT01918371
- Testing
- Anti-VEGF
- Where
- United States
- Volunteers
- 323 people, healthy volunteers welcome
- Sponsor
- Allergan
Deep Vein Thrombosis, Fibrillation, Atrial
Odiparcil For The Prevention Of Venous Thromboembolism
Odiparcil is being studied to determine if it can prevent blood clots from forming after a total knee replacement and also to prove that odiparcil is safe.
- Conditions
- Deep Vein Thrombosis, Fibrillation, Atrial, Venous Thromboembolism, Pulmonary Embolism
- Trial name
- NCT00244725
- Testing
- Odiparcil, Warfarin, Coumadin
- Where
- 101 sites in United States, Australia and 11 more
- Volunteers
- 961 people
- Sponsor
- GlaxoSmithKline